Sugi Predict

Sugi Predict / Targets / PHPT1

PHPT1

14 kDa phosphohistidine phosphatase · Q9NRX4 · PHPT1 on Sugi Atlas →

1,864 patent compounds predicted against PHPT1, 1,351 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Acetarsone Acetarsone (SCHEMBL156373) 1.00 2/20
Roxarsone Roxarsone (SCHEMBL158026) 1.00 2/20
Acetarsone Acetarsone (SCHEMBL9770650) 0.83 2/20
Slazinic Acid Slazinic Acid (SCHEMBL3801772) 0.77 2/20
Roxarsone Roxarsone (SCHEMBL11204002) 0.75 2/20
SCHEMBL6888417 SCHEMBL6888417 0.62 2/20
SCHEMBL2113434 SCHEMBL2113434 0.58 2/20
SCHEMBL2618036 SCHEMBL2618036 0.58 2/20
SCHEMBL2113613 SCHEMBL2113613 0.55 2/20
SCHEMBL2618037 SCHEMBL2618037 0.55 2/20
Psoromic Acid Psoromic Acid (SCHEMBL2113679) 0.53 2/20
SCHEMBL3440815 SCHEMBL3440815 0.53 2/20
SCHEMBL2111729 SCHEMBL2111729 0.53 2/20
SCHEMBL2114540 SCHEMBL2114540 0.53 2/20
SCHEMBL2112898 SCHEMBL2112898 0.51 2/20
SCHEMBL2113620 SCHEMBL2113620 0.51 2/20
SCHEMBL2114883 SCHEMBL2114883 0.51 2/20
SCHEMBL2115376 SCHEMBL2115376 0.51 2/20
SCHEMBL2112603 SCHEMBL2112603 0.51 2/20
SCHEMBL2112192 SCHEMBL2112192 0.50 2/20

Clinical trials — most relevant to PHPT1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate PHASE4COMPLETED
Bisphosphonate Prior to Parathyroidectomy in Primary Hyperparathyroidism PHASE4RECRUITING
Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) PHASE2WITHDRAWN
Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism nanUNKNOWN
Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism nanRECRUITING
QoL and Cognitive Function in Patients With Hypoparathyroidism nanCOMPLETED
Studying Phosphorus Metabolism nanCOMPLETED
Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia) nanUNKNOWN
European Multicentric Study on Parathyroid Carcinoma nanUNKNOWN
Gait and Balance Parameters Before and After Parathyroidectomy in Patients With Primary Hyperparathyroidism nanCOMPLETED
The PORTRAIT Study nanUNKNOWN
Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in Greek nanNOT_YET_RECRUITING
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING
Planetary Habitat Simulation: Bone Metabolism Studies nanCOMPLETED
Differentially Expressed Proteins in Sporadic Parathyroid Tumors nanUNKNOWN
Study of the Regulation of Parathyroid Hormone Secretion in Pseudohypoparathyroidism nanCOMPLETED
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) nanCOMPLETED
Genetic Study of Families Affected by Paget's Disease of Bone nanCOMPLETED
Characterisation of Adult-Onset Hypophosphatasia nanCOMPLETED
Hypophosphatemic Rickets in Norway nanUNKNOWN
The Role Of FGF23, Klotho, And Sclerostin In Kidney Stone Formers nanUNKNOWN
Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome nanUNKNOWN
Hypoparathyroidism Natural History Study nanRECRUITING
Type 1 Multiple Endocrine Neoplasia Cohort Study nanUNKNOWN
Radius Loading in Primary Hyperparathyroidism nanCOMPLETED
Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia nanUNKNOWN
Studies of Inherited Diseases of Metabolism nanCOMPLETED
Physiologic Regulation of FGF-23 nanCOMPLETED
OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism nanCOMPLETED
Effect of Parathyroidectomy on Cardiovascular Health nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PHPT1 binder may also engage these)

ProteinNameSimilarity
P59083 — 1.000 P59083 →
Q32PA4 — 1.000 Q32PA4 →
Q5R8L6 — 0.997 Q5R8L6 →
P83468 — 0.997 P83468 →
Q9DAK9 — 0.995 Q9DAK9 →
Q4R512 — 0.956 Q4R512 →
Q00PJ7 — 0.953 Q00PJ7 →
Q9JKB8 — 0.952 Q9JKB8 →
Q66H61 — 0.952 Q66H61 →
A4D7Q3 — 0.951 A4D7Q3 →
Q5ZKG8 — 0.951 Q5ZKG8 →
Q9NWV4 — 0.951 Q9NWV4 →
A0M8V0 — 0.950 A0M8V0 →
Q28250 — 0.950 Q28250 →
Q502H1 — 0.950 Q502H1 →
Q5ZKY2 — 0.950 Q5ZKY2 →
P25229 — 0.949 P25229 →
Q9H269 — 0.949 Q9H269 →
O62703 — 0.949 O62703 →
A4GWN3 — 0.949 A4GWN3 →
Q2QLF0 — 0.949 Q2QLF0 →
Q3T1K5 — 0.948 Q3T1K5 →
Q6PFS7 — 0.948 Q6PFS7 →
Q5R6F1 — 0.948 Q5R6F1 →
ATG7 Ubiquitin-like modifier-activating enzyme ATG7 0.948 landscape →
Q80YV4 — 0.948 Q80YV4 →
Q8BHG2 — 0.948 Q8BHG2 →
Q5BJI9 — 0.948 Q5BJI9 →
Q2QLH5 — 0.947 Q2QLH5 →
Q9CYN2 — 0.947 Q9CYN2 →